Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Mediwound ( (MDWD) ) has issued an update.
On May 21, 2025, MediWound Ltd. announced its first quarter financial results and provided a corporate update. The company reported a revenue of $4 million for the quarter and reaffirmed its full-year revenue guidance of $24 million. Key developments include the ongoing VALUE Phase III trial for EscharEx, a significant collaboration with Kerecis, and the expansion of NexoBrid manufacturing capacity, expected to reach full operational capacity by the end of 2025. The company also highlighted increased U.S. adoption of NexoBrid and presented clinical data on its use during the Israel–Hamas conflict. Despite a decrease in revenue compared to the previous year, MediWound reported an improved net loss due to non-cash financial income.
The most recent analyst rating on (MDWD) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Mediwound stock, see the MDWD Stock Forecast page.
Spark’s Take on MDWD Stock
According to Spark, TipRanks’ AI Analyst, MDWD is a Neutral.
Mediwound’s stock score is influenced by its financial struggles, including persistent losses and cash flow challenges, which are major concerns. While technical indicators show some positive momentum, and strategic partnerships and clinical progress offer future potential, the current valuation and financial health are significant risks. The stock’s potential is contingent on improved financial stability and successful product commercialization.
To see Spark’s full report on MDWD stock, click here.
More about Mediwound
MediWound Ltd. is a global leader in next-generation enzymatic therapeutics for tissue repair. The company focuses on developing and commercializing products for wound care, with key offerings including EscharEx for venous leg ulcers and NexoBrid for burn treatment. MediWound collaborates with leading global wound care companies and emphasizes strategic manufacturing investments to support sustained growth.
Average Trading Volume: 80,969
Technical Sentiment Signal: Buy
Current Market Cap: $221.7M
For a thorough assessment of MDWD stock, go to TipRanks’ Stock Analysis page.